$1.89-0.03 (-1.56%)
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States.
Sintx Technologies, Inc. in the Healthcare sector is trading at $1.89 with a market capitalization of $10M. Wall Street consensus targets $9.12 (4 analysts), implying a +382.8% move over the next 12 months. The stock is currently near its 52-week low of $1.80, remaining 39.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $300,000β | $188,000β | $150,000β | $100,000β | $291,000 |
| Gross Profit | $64,000β | $86,000β | $35,000β | $6,000β | $45,000 |
| Operating Income | -$3.21Mβ | -$2.32Mβ | -$3.35Mβ | -$2.67Mβ | -$2.38M |
| Net Income | -$2.82Mβ | -$2.21Mβ | -$3.54Mβ | -$2.32Mβ | -$2.29M |
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. ...
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -24.00% and +6.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 0.00% and +4.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?